Standout Papers
- Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies (2012)
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 (2011)
Immediate Impact
1 by Nobel laureates 11 from Science/Nature 68 standout
Citing Papers
Targeting protein–ligand neosurfaces with a generalizable deep learning tool
2025 StandoutNature
Cell death
2024 Standout
Works of Ahmed Hamdy being referenced
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib
2014
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
2012 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Ahmed Hamdy | 1903 | 1565 | 510 | 720 | 56 | 2.5k | |
| Raquel Izumi | 1782 | 1487 | 561 | 631 | 71 | 2.5k | |
| Lawrence D. Piro | 1644 | 1246 | 914 | 841 | 59 | 2.8k | |
| L. E. Robertson | 1811 | 1142 | 593 | 708 | 40 | 2.8k | |
| Ulrich Jäger | 1417 | 1337 | 523 | 658 | 85 | 2.4k | |
| MJ Keating | 1677 | 977 | 849 | 717 | 54 | 3.0k | |
| Loree Larratt | 1258 | 1000 | 612 | 809 | 80 | 3.0k | |
| Laurence Elias | 1425 | 1228 | 799 | 885 | 72 | 3.2k | |
| J M Bennett | 1757 | 1166 | 927 | 865 | 39 | 4.0k | |
| Stefan Faderl | 1700 | 1017 | 533 | 736 | 113 | 3.5k | |
| John C. Byrd | 1326 | 1000 | 708 | 529 | 79 | 3.6k |
All Works
Login with ORCID to disown or claim papers
Loading papers...